Amryt Pharma PLC New Distribution Agreement Signed (2515D)
30 January 2018 - 6:00PM
UK Regulatory
TIDMAMYT
RNS Number : 2515D
Amryt Pharma PLC
30 January 2018
30 January 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
New Distribution Agreement Signed
Completing Lojuxta Footprint in Eastern Europe
Amryt, a biopharmaceutical company focused on rare and orphan
diseases, is pleased to announce that it has signed an exclusive
distribution agreement for Lojuxta(R) (lomitapide) covering Romania
and Bulgaria with Romastru Trading SRL ("Romastru"), a
Bucharest-based pharmaceutical services company, part of Pharaon
Healthcare Europe, a conglomerate which provides a wide range of
services, including medical, marketing research, storage and
distribution.
This is the fourth distribution agreement signed by Amryt in the
last three months, and it broadens further the Company's
distribution footprint for Lojuxta in Central and Eastern Europe.
The Company aims to complete further agreements across its
in-licenced territories in Europe, Middle East and Africa as the
year progresses.
Lojuxta is a treatment for Homozygous Familial
Hypercholesterolemia ("HoFH"), the rare, life-threatening, genetic
cholesterol disorder, and Amryt estimates that there are
approximately 30 patients with HoFH in Romania and Bulgaria
combined.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma,
said:
"We are pleased to have signed this agreement with Romastru, a
long-established pharmaceutical services company based in
Bucharest. Romastru's reach across Romania and Bulgaria means that
we can now provide comprehensive access to Lojuxta for adult
patients suffering from HoFH in these territories."
Enquiries:
C/o KTZ Communications
Amryt Pharma plc (details below)
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Edward Mansfield, Mark
Percy
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene
Bermont-Penn, Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty biopharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the European Economic Area, Middle
East and North Africa, Turkey and Israel. Lojuxta is used to treat
a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia, which impairs the body's ability to remove
LDL cholesterol ("bad" cholesterol) from the blood. This typically
results in extremely high blood LDL cholesterol levels, leading to
aggressive and premature narrowing and blocking of arterial blood
vessels. If left untreated, heart attack or sudden death may occur
in childhood or early adulthood.
Amryt's lead drug candidate, AP101, is a potential treatment for
Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children for which there is currently no
treatment. It is currently in Phase 3 clinical trials. The global
market opportunity for EB is estimated to be in excess of EUR 1.3
billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAKFNALPPEFF
(END) Dow Jones Newswires
January 30, 2018 02:00 ET (07:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024